Interestingly, we demonstrated that FBXO2 was down-regulated generally in BC, overexpression of FBXO2 stands for better RFS in Luminal B and HER2 types BRCA, while the expression was correlated with tumor stage in patients with BC. This evidence concerns the gene ERBB2 and breast cancer.